An index of frontier and emerging AI labs.
Bio / AI drug discovery
AI for drug discovery, spun out of DeepMind. Alphabet subsidiary led by Demis Hassabis. Closed a $2.1B Series B led by Thrive Capital on May 12, 2026 (MGX, Temasek, CapitalG, UK Sovereign AI Fund); reportedly valued the company in the $15–20B range.
| Name | Isomorphic Labs |
|---|---|
| Space | Bio / AI drug discovery |
| Founded | 2021 |
| Latest valuation | >$15B |
| Stage | — |
| Status | active |
| HQ | London |
| Founders | Demis Hassabis |
| Website | https://www.isomorphiclabs.com |
| Careers | https://www.isomorphiclabs.com/careers |
| — | |
| X / Twitter | — |
| Date | Round | Amount ($M) | Valuation | Confidence | Source |
|---|---|---|---|---|---|
| — | — | — | >$15B | reported | — |
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-14 | added | Isomorphic Labs added to tracker Latest valuation: >$15B. | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |
| Chai Discovery | $1.3B | 2024 |
| Earendil Labs | ~$1B | 2023 |
| EvolutionaryScale | >$1B | 2024 |
| Genesis Therapeutics | ~$1B | 2019 |